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Abstract: The solubility, absorption and distribution of a drug are involved in the basic 
aspects of oral bioavailability Solubility is an essential characteristic and influences the 
efficiency of the drug. Over the last ten years, the number of poorly soluble drugs has 
steadily increased. One of the progressive ways for increasing oral bioavaibility is the 
technique of nanoparticle preparation, which allows many drugs to thus reach the intended 
site of action. Candesartan cilexetil and atorvastatin, belonging to class II of the 
biopharmaceutical classification system, were chosen as model active pharmaceutical 
ingredients in this study. Forty samples were prepared either by antisolvent 
precipitation/solvent evaporation method or by the emulsion/solvent evaporation technique 
with various commonly used surface-active excipients as nanoparticle stabilizers. All 
samples were analyzed by means of dynamic light scattering. The particle size of the 
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determined 36 nanoparticle samples was to 574 nm, whereas 32 samples contained 
nanoparticles of less than 200 nm. Relationships between solvents and excipients used and 
their amount are discussed. Based on the results the investigated solvent evaporation 
methods can be used as an effective and an affordable technique for the preparation  
of nanoparticles. 
Keywords: candesartan cilexetil; atorvastatin; nanoparticles; solvent evaporation; 
excipients; dynamic light scattering 
 
1. Introduction 
For ensure the pharmacological activity of an active pharmaceutical ingredient (API), the solubility 
of the API in physiological liquids is required, so that the API can be available at the place of 
absorption. Solubility in various solvents is a characteristic property of a particular compound. The 
solubility of a compound in water correlates to a great extent with the solubility in physiological 
liquids and is the first limiting factor for good absorption and biodistribution. Contrary to these facts, 
over the last ten years, the number of poorly soluble drugs has steadily increased. Estimates suggest 
that 40% of the drugs in the pipelines have solubility problems. Literature states that about 60% of all 
drugs coming directly from synthesis nowadays are poorly soluble [1–3]. 
One of the progressive ways how to increase the solubility of an APIs is the preparation of drug 
nanoparticles. The technique of nanoparticle drug delivery allows many pharmacological agents to 
reach the desired site of action. APIs are either adjusted alone till nano size and administered in 
nanoparticle oral dosage forms or attached/incorporated into nanoparticles prepared from inert 
materials which serve as a universal drug delivery system. The advantages of nanotechnology are as 
follows: (i) increased bioavailability (quick dissolution; improved penetration through membranes); 
(ii) lower doses; (iii) lower toxicity; (iv) targeted biodistribution; (v) reduction of influence of food on 
variability; (vi) quicker development of formulations [2,4–7]. Nanoparticles of less than 200 nm are of 
practical importance [8–13]. A great problem is the insufficiently investigated possible toxicity of 
nanoparticles. The toxicity is dependent on the shape and surface properties of nanoparticles, because 
both can influence nanoparticle-cell interactions as well as the rate of penetration to cells. Among the 
various nanoparticle forms nanotubes were found to be one of the most toxic nanoparticle shapes [14–17]. 
A wide range of techniques have been developed for the preparation of nanomaterials. These 
methods are typically grouped into two categories: top-down (generally dispergation processes)  
[11–13,18–21] and bottom-up (generally precipitation processes) [11–13,18,22–24], whereas the latter 
is by far the most popular in the preparation of nanoparticles. In bottom-up methods, nanoparticles can 
be produced by crystallization/precipitation and solvent evaporation. Spray drying, evaporative 
precipitation into aqueous solution, microemulsions or supercritical fluid technology belong to the 
solvent evaporation methods. The liquid antisolvent (LAS) precipitation process is a noteworthy 
method that has been extensively studied. An excellent review dealing with this technique was 
published by Thorat et al. [25]. The current paper is aimed at verification of conditions of an effective 
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and an affordable technique for the preparation of nanoparticles by solvent evaporation as was 
discussed recently [26]. 
A polar and nonpolar solvent were used in our research, therefore the exact principle of the applied 
solvent evaporation method is dependent on the water-based system, including or not an aqueous 
miscible organic solvent. The polar acetone (AC) and nonpolar dichloromethane (DCM) were chosen 
as the most suitable solvents for easy dissolution of the APIs, so two different possible mechanisms 
can be supposed for the nanoparticle synthesis. When API is dissolved in AC and then mixed with 
water containing a stabilizer, nanoparticles are formed spontaneously and immediately upon mixing. 
This method can be called antisolvent precipitation/solvent evaporation, and the procedure is in 
principle similar to the evaporative precipitation into aqueous solution [27,28] or the liquid antisolvent 
precipitation [25]. When the API is dissolved in DCM and then mixed with water containing 
stabilizers, an emulsion (o/w type) is formed; API is clustered by the excipient, which results in the 
encapsulation of the API into nano-vesicula. This combination of emulsification and solvent 
evaporation nanoparticle synthesis can be called emulsion/solvent evaporation [19,29].  
The model APIs candesartan cilexetil (I) and atorvastatin calcium (II) were chosen as 
representatives of poorly aqueous soluble compounds belonging to class II drugs of the 
biopharmaceutical classification system (BCS). Drugs of the mentioned class are characterized by low 
aqueous solubility and high permeability [30]. Candesartan (2-ethoxy-1-({4-[2-(2H-1,2,3,4-tetrazol-5-
yl)phenyl]phenyl}methyl)-1H-1,3-benzodiazole-6-carboxylic acid) is an angiotensin II receptor 
antagonist used mainly for the treatment of hypertension. The prodrug candesartan cilexetil, see Figure 1, 
is marketed by AstraZeneca and Takeda Pharmaceuticals, commonly under the trade names Blopress®, 
Atacand®, Amias®, and Ratacand®. The use of a prodrug form increases the bioavailability of 
candesartan. Despite this, its absolute oral bioavailability is relatively poor (approx. 15%) [31,32]. 
Atorvastatin [(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-
3,5-dihydroxyheptanoic acid] inhibits HMG-CoA reductase and thus causes a decrease of cholesterol 
in the body. Atorvastatin is used as a calcium salt, see Figure 1, and is marketed by Pfizer under  
the trade names Lipitor® or Sortis®. The low plasma concentration (approx. 12%) of atorvastatin is 
especially caused by an extensive first-pass metabolism in the liver, nevertheless the overall solubility 
of atorvastatin is strictly pH-dependent (many atorvastatin solid dosage forms are buffered, e.g., by 
carbonates), and administration with food produces a 25% reduction of atorvastatin absorption [33,34].  
As mentioned, both APIs are BCS class II drugs, hence their oral bioavailability is solubility rate 
limited [30–32,35–37]. For enhancement of solubility of candesartan cilexetil various approaches can 
be used, such as pectin complexes [38], self-emulsifying drug delivery systems [39] or development of 
nanoparticle formulations [7,40]. The solubility of atorvastatin calcium can be enhanced, for example, 
using an amorphous API [41], by application of the liquisolid technique [42], formulation of  
self-microemulsifying drug delivery systems [43], utilization of drug-polymer interactions found due 
to physical mixing [44] or preparation of amorphous nanoparticles [45]. 
Various types of surface-active excipients were used as nanoparticle stabilizers and relationships 
between a substance, a solvent and a used excipient are discussed. Used excipients represent various 
classes of pharmaceutical adjutants (emulsifiers/viscosity modifiers/thickeners, nonionic or anionic 
surfactants) that can be utilized as solubility modifying compounds/nanoparticle stabilizers, such as 
Tween 80 (TW), sodium dodecyl sulfate (SDS), macrogol 6000 (PEG), sodium carboxymethyl 
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cellulose (SCMC) and sodium salt of carboxymethyl dextran (SCMD). The main criteria for excipient 
selection were its pharmaceutical safety (all excipients are GRAS, Generally Recognized as Safe, 
substances) and their affordability. Based on a previous study 5% and 10% concentrations of each 
excipient were chosen [26]. The optimal concentration of surfactant is important for optimal particles 
wetting. If the concentration is too low, particles float on the surface. If the concentration is too high 
bubbles appear [46]. 
Figure 1. Structures of candesartan cilexetil as prodrug and atorvastatin calcium salt. 
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2. Results and Discussion 
Both model APIs I and II dissolved in dichloromethane and acetone (2% concentration) were added 
to aqueous solutions (5%, 10% concentration) of excipients, i.e., eight samples were prepared with 
each excipient. The final API:excipient ratios were 1:2.5 (2%:5%), 1:5 (2%:10%). The systems were 
stirred for 10 min at 35 °C; afterwards the mixtures were transferred to an ultrasonic bath, where they 
were mixed again for 40 min, and simultaneously the organic solvent was evaporated (to final 10 mL 
sample volume) by self-warming of the ultrasonic bath. Then all the samples were characterized by 
dynamic light scattering [46]. All the results are presented in Tables 1–5 and Figures 2–8.  
Table 1. Particle size (x10, x90 [nm]) of APIs I, II and concentration [%] of Tween 80 in 
dichloromethane (DCM) or acetone (AC). All the presented results are reported as the 
medium value of four independent measurements. The results of nano-size samples are 
expressed as the mean ± SD (n = 4 measurements). The SDs of micro-size samples are  
not indicated due to the measurability range of Nanophox. Samples that contained 
nanoparticles <200 nm are bolded; nanoparticles <10 nm are indicated by asterisk.  
(S.No. = sample number). 
API/Solvent 
Tween 80  
S.No. 
5% 
S.No. 
10%  
x10 x90 x10 x90 
Pa
rt
ic
le
 si
ze
 
[n
m
] I/DCM 1 160 ± 4.8 219 ± 5.6 2 14 ± 0.4 16 ± 0.5 * 
I/AC 3 3183 6531 4 2 ± 0.1 3 ± 0.1 * 
II/DCM 5 97 ± 2.9 142 ± 4.3 6 145 ± 4.4 213 ± 6.4 
II/AC 7 101 ± 3.0 111 ± 3.3 8 3 ± 0.1 4 ± 0.1 * 
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Table 2. Particle size (x10, x90 [nm]) of APIs I, II and concentration [%] of sodium dodecyl 
sulfate in dichloromethane (DCM) or acetone (AC). All the presented results are reported 
as the medium value of four independent measurements. The results of nano-size samples 
are expressed as the mean ± SD (n = 4 measurements). The SDs of micro-size samples  
are not indicated due to the measurability range of Nanophox. Samples that contained 
nanoparticles <200 nm are bolded; nanoparticles <10 nm are indicated by asterisk.  
(S.No. = sample number). 
API/Solvent 
Sodium dodecyl sulfate  
S.No. 
5% 
S.No. 
10%  
x10 x90 x10 x90 
Pa
rt
ic
le
 si
ze
 
[n
m
] I/DCM 9 90 ± 2.7 99 ± 3.0 10 2 ± 0.1 3 ± 0.1 * 
I/AC 11 4 ± 0.1 5 ± 0.2 * 12 1 ± 0.03 2 ± 0.1 * 
II/DCM 13 1 ± 0.03 2 ± 0.1 * 14 90 ± 2.7 99 ± 3.0 
II/AC 15 2 ± 0.1 2 ±0.1 * 16 2 ± 0.1 4 ± 0.1 * 
Table 3. Particle size (x10, x90 [nm]) of APIs I, II and concentration [%] of macrogol 6000 
in dichloromethane (DCM) or acetone (AC). All the presented results are reported as the 
medium value of four independent measurements. The results of nano-size samples are 
expressed as the mean ± SD (n = 4 measurements). The SDs of micro-size samples are not 
indicated due to the measurability range of Nanophox. Samples that contained 
nanoparticles <200 nm are bolded; nanoparticles <10 nm are indicated by asterisk.  
(S.No. = sample number). 
API/Solvent 
Macrogol 6000  
S.No. 
5% 
S.No. 
10%  
x10 x90 x10 x90 
Pa
rt
ic
le
 si
ze
 
[n
m
] I/DCM 17 2 ± 0.1 3 ± 0.1 * 18 2 ± 0.1 3 ± 0.1 * 
I/AC 19 2 ± 0.1 3 ± 0.1 * 20 156 ± 4.7 206 ± 6.2 
II/DCM 21 1639 1804 22 5231 5755 
II/AC 23 6 ± 0.2 8 ± 0.2 * 24 4 ± 0.1 6 ± 0.2 * 
Table 4. Particle size (x10, x90 [nm]) of APIs I, II and concentration [%] of sodium 
carboxymethyl cellulose in dichloromethane (DCM) or acetone (AC). All the presented 
results are reported as the medium value of four independent measurements. The results of 
nano-size samples are expressed as the mean ± SD (n = 4 measurements). The SDs of 
micro-size samples are not indicated due to the measurability range of Nanophox. Samples 
that contained nanoparticles <200 nm are bolded; nanoparticles <10 nm are indicated by 
asterisk. (S.No. = sample number). 
API/Solvent 
Sodium carboxymethyl cellulose  
S.No. 
5% 
S.No. 
10%  
x10 x90 x10 x90 
Pa
rt
ic
le
 si
ze
 
[n
m
] I/DCM 25 11 ± 0.3 13 ± 0.4 26 2 ± 0.1 3 ± 0.1 * 
I/AC 27 1 ± 0.03 2 ± 0.1 * 28 32 ± 1.0 35 ± 1.1 
II/DCM 29 401 ± 12 574 ± 17 30 1 ± 0.03 2 ± 0.1 * 
II/AC 31 6 ± 0.2 7 ± 0.2 * 32 27 ± 0.8 30 ± 0.9 
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Table 5. Particle size (x10, x90 [nm]) of APIs I, II and concentration [%] of sodium 
carboxymethyl dextran in dichloromethane (DCM) or acetone (AC). All the presented 
results are reported as the medium value of four independent measurements. The results of 
nano-size samples are expressed as the mean ± SD (n = 4 measurements). The SDs of 
micro-size samples are not indicated due to the measurability range of Nanophox. Samples 
that contained nanoparticles <200 nm are bolded; nanoparticles <10 nm are indicated by 
asterisk. (S.No. = sample number). 
API/Solvent 
Sodium carboxymethyl dextran  
S.No. 
5% 
S.No. 
10%  
x10 x90 x10 x90 
Pa
rt
ic
le
 si
ze
 
[n
m
] I/DCM 33 2 ± 0.1 2 ± 0.1 * 34 1 ± 0.03 1 ± 0.03 * 
I/AC 35 3 ± 0.1 4 ± 0.1 * 36 39 ± 1.2 43 ± 1.3 
II/DCM 37 2 ± 0.1 2 ± 0.1 * 38 9345 10281 
II/AC 39 2 ± 0.1 3 ± 0.1 * 40 70 ± 2.1 77 ± 2.3 
Figure 2. Dependence of particle size (x90 [nm]) of model APIs I, II on concentration [%] 
of Tween 80 in dichloromethane (DCM) or acetone (AC). (A) Samples are grouped 
according to APIs; (B) samples are grouped according to excipient percentage. For clarity 
sake, the values on y-axis are only to 300 nm. 
 
Figure 3. Dependence of particle size (x90 [nm]) of model APIs I, II on concentration [%] 
of sodium dodecyl sulfate in dichloromethane (DCM) or acetone (AC). (A) Samples are 
grouped according to APIs; (B) samples are grouped according to excipient percentage. 
For clarity sake, the values on y-axis are only to 100 nm. 
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Figure 4. Dependence of particle size (x90 [nm]) of model APIs I, II on concentration [%] 
of macrogol 6000 in dichloromethane (DCM) or acetone (AC). (A) Samples are grouped 
according to APIs; (B) samples are grouped according to excipient percentage. For clarity 
sake, the values on y-axis are only to 300 nm. 
 
Figure 5. Dependence of particle size (x90 [nm]) of model APIs I, II on concentration [%] 
of sodium carboxymethyl cellulose in dichloromethane (DCM) or acetone (AC).  
(A) Samples are grouped according to APIs; (B) samples are grouped according to 
excipient percentage. For clarity sake, the values on y-axis are only to 100 nm. 
 
Figure 6. Dependence of particle size (x90 [nm]) of model APIs I, II on concentration [%] 
of sodium carboxymethyl dextran in dichloromethane (DCM) or acetone (AC).  
(A) Samples are grouped according to APIs; (B) samples are grouped according to 
excipient percentage. For clarity sake, the values on y-axis are only to 100 nm. 
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Figure 7. Dependence of particle size (x90 [nm]) of candesartan cilexetil (I) on 
concentration [%] of Tween 80 (TW), sodium dodecyl sulfate (SDS), macrogol 6000 
(PEG), sodium carboxymethyl cellulose (SCMC), sodium carboxymethyl dextran (SCMD) 
in dichloromethane (DCM) or acetone (AC). For clarity sake, the values on y-axis are only 
to 50 nm. 
 
Figure 8. Dependence of particle size (x90 [nm]) of atorvastatin calcium (II) on 
concentration [%] of Tween 80 (TW), sodium dodecyl sulfate (SDS), macrogol 6000 
(PEG), sodium carboxymethyl cellulose (SCMC), sodium carboxymethyl dextran (SCMD) 
in dichloromethane (DCM) or acetone (AC). For clarity sake, the values on y-axis are only 
to 50 nm. 
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1–5. According to the results, when micro-size samples (3, 21, 22, 38) were eliminated, the average 
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nanoparticles are spheres, because the size in dynamic light scattering represents the hydrodynamic 
diameter of the particle. All samples were dispersed by ultrasonics directly before the measurement to 
avoid possible re-agglomeration. Stabilization of the dispersed samples was achieved by surfactants 
and by the constant temperature. The measuring cell was equilibrated at 25 °C, so the Brown motion of 
nanoparticles is influenced just by their size. 
From Figures 2A–6A it can be stated that generally particle size is not dependent on the type of 
model API, but it is partially influenced by the type and concentration of the excipient utilized. 
Nevertheless, it can be supposed that in the case of candesartan cilexetil (I) smaller particles were 
found, especially when atorvastatin calcium (II) and SDS, PEG and SCMC in dichloromethane were 
used, as it is illustrated in Figures 7 and 8, where the dependences of the particle size of individual 
APIs I and II on the concentrations of individual excipients are shown. This fact is probably caused by 
the solvent used, because dichloromethane has less advantageous properties in comparison with 
acetone, as discussed below. 
Table 6 summarizes results of all the samples of nanoparticles under 900 nm size depending on 
solvents and the type and amount of excipients. As the aim of this contribution is specification of 
suitable conditions for nanoparticles preparation, in Table 6 generated nanoparticles are not divided 
according to used APIs. 
Table 6. View of formed samples of nanoparticles (≤900 nm) depending on solvents and 
type and amount of excipients. (conc. = concentration; excp. = excipient; dichloromethane = 
DCM; acetone = AC; Tween 80 = TW; sodium dodecyl sulfate = SDS; macrogol 6000 = 
PEG; sodium carboxymethyl cellulose = SCMC; sodium carboxymethyl dextran = SCMD). 
Excp. 
conc./type 
DCM 
Sum 
total 
Overall 
average 
x90 [nm] 
AC
Sum 
total 
Overall 
average 
x90 [nm] 
5% 10% 5% 10%
number of 
nanop. samples 
number of 
nanop. samples 
TW 2 2 4 147 1 2 3 39 
SDS 2 2 4 51 2 2 4 3 
PEG 1 1 2 3 2 2 4 56 
SCMC 2 2 4 148 2 2 4 18 
SCMD 2 1 3 2 2 2 4 32 
Sum total 9 8 17 351 9 10 19 148 
Overall 
average 
x90 [nm] 
117 42 160  70 80 16 41 57 
 30 
29 
After summation of all the results it can be concluded that from 40 prepared mixtures 36 samples 
contained nanoparticles (see Tables 1–5), from which 32 samples contained nanoparticles smaller than 
200 nm (see Tables 1–5, bolded values). Nanoparticles under 10 nm were determined in 22 samples 
from 32, see Tables 1–5 (asterisked bolded values). 
Based on the results listed in Table 6 and Figures 7 and 8 it can be generally stated that the solvent 
used plays the crucial role in generation of nanoparticles. This fact was not so evident in the previous 
study, where only steroid-like compounds were investigated [26]. This effect of solvent was significant 
in the case of atorvastatin calcium (II), which is a salt and thus by its chemical nature absolutely 
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different from other investigated model compounds. It depends on the used solvent, if the system  
is single-phase (acetone/water) or biphasic (dichloromethane/water, o/w type), thus whether 
nanoparticles will be formed spontaneously and immediately upon mixing or if emulsions will be 
generated and nanoparticles will not be formed spontaneously but after energy input, e.g., ultrasonic. 
As the way of preparation was the same (mixing and ultrasounding), it is evident from the results  
that the polar solvent acetone is preferable to nonpolar dichloromethane, i.e., that antisolvent 
precipitation/solvent evaporation method is a more convenient/versatile way for preparation of 
nanoparticles than the emulsion/solvent evaporation technique. Results with APIs dissolved in acetone 
provided more nanoparticle samples comparable with dichloromethane (19/17), and the particle size of 
APIs dissolved in acetone was significantly smaller than that of APIs dissolved in dichloromethane 
(148/351). 
From all the results (see Figures 7 and 8) it is evident that the usage of Tween 80, especially at 5% 
concentration (ratio 1:2.5), and sodium carboxymethyl dextran, especially at 10% concentration  
(ratio 1:5), was the least advantageous as discussed previously [26]. In other cases both 5% and 10% 
concentrations of excipients provided similar results. Surprisingly, macrogol 6000 did not afford as 
good results as expected [26]. Sodium dodecyl sulfate and sodium carboxymethyl cellulose can be 
universally used as nanoparticle stabilizers both in dichloromethane and acetone. 
3. Experimental 
3.1. General 
Both APIs were obtained from Zentiva (Prague, Czech Republic), all excipients were purchased 
from Sigma-Aldrich (Prague, Czech Republic). Dichloromethane was purchased from Merck 
(Darmstadt, Germany). Acetone was purchased from LachNer (Neratovice, Czech Republic). All 
compounds as well as solvents were of analytical grade. H2O-HPLC—Mili-Q Grade was used as a 
solvent of excipients. Particle sizes of all the final samples were determined using dynamic  
light scattering in a Sympatec Photon Cross-correlation Sensor Nanophox (Sympatec GmbH,  
System-Partikel-Technik, Clausthal-Zellerfeld, Germany), He-Ne laser 632.8 μm, intensity max.  
10 mW. The measurement cell was equilibrated at 25 °C. 
3.2. Synthesis 
Standardized General Procedure for Preparation of Nanoparticles 
Tween 80, sodium dodecyl sulfate (SDS), macrogol 6000 (PEG), sodium carboxymethyl cellulose 
(SCMC) and sodium carboxymethyl dextran (SCMD) were used as excipients. Each excipient (0.5 g or 
1.0 g) was dissolved in water (10 mL), and two solutions with concentrations 5% and 10% were 
prepared. Candesartan cilexetil and atorvastatin calcium (0.2 g) were dissolved in dichloromethane or 
acetone (10 mL), i.e., 2% solutions were prepared. The solutions of the substances in dichloromethane 
(DCM) or acetone (AC) were slowly dropped (2 mL/min) to the aqueous solutions of excipients that 
were stirred (600 rpm). Then the system was stirred (600 rpm) for 10 min at 35 °C, after which the 
mixtures were transferred to an ultrasonic bath in the fume chamber, where they were mixed again for 
Molecules 2012, 17 13231 
 
 
40 min, and simultaneously organic solvent was evaporated. The final volume of the aqueous sample 
was 10 mL. The particle size of nanonized substances in samples was evaluated by means of 
Nanophox. All samples were dispersed by ultrasonics directly before the measurement. Measurements 
were repeated four times. All the presented results are reported as the medium value of these four 
independent measurements. The results of nano-size samples are expressed as the mean ± SD (n = 4 
measurements). Standard deviations of micro-size samples are not indicated due to the measurability 
range of Nanophox. All the results are summarized in Tables 1–5 and illustrated in Figures 2–8. 
4. Conclusions 
Forty samples of candesartan cilexetil (I) and atorvastatin calcium (II) were prepared by solvent 
evaporation in media Tween 80, sodium dodecyl sulfate, macrogol 6000, sodium carboxymethyl 
cellulose and sodium carboxymethyl dextran. All the samples were analyzed by a Nanophox 
spectrometer. According to the cumulative distribution x90, 36 samples contained nanoparticles;  
32 samples contained nanoparticles <200 nm; and 22 samples contained nanoparticles <10 nm. The 
used solvent played a crucial role in generation of nanoparticles. The polar solvent acetone was 
considerably more advantageous than nonpolar dichloromethane, i.e., the antisolvent precipitation/ 
solvent evaporation method is a more convenient/versatile way for preparation of nanoparticles than 
the emulsion/solvent evaporation technique. The selected conditions are convenient for formation of 
nanoparticles, and the excipients used (except Tween 80) are in principal applicable as nanoparticle 
stabilizers. Sodium dodecyl sufate and sodium carboxymethyl cellulose at both concentrations tested, 
5% and 10%, i.e., API:excipient ratios of 1:2.5, 1:5, can be universally used as nanoparticle-stabilizing 
agents. It can be concluded that the investigated solvent evaporation method can be used as an 
effective and an affordable technique for the preparation of nanoparticles. After selection of a 
convenient non-toxic organic solvent this method can be scaled up. Nanoparticles of candesartan 
cilexetil or atorvastatin prepared in this manner would be subsequently used for nanoparticle 
formulations with supposed enhanced bioavailability. 
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